The Securities and Exchange Commission has extended its ongoing investigation of Northwest Biotherapeutics (NWBO) and now appears to be probing the biotech’s conduct related to its clinical trial of an experimental brain cancer treatment.

The disclosure of even more SEC scrutiny comes at a perilous time for Northwest Bio. On Friday, the company is asking shareholders to approve a financial bailout plan likely needed to stave off insolvency.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy